Overview
Prader-Willi syndrome due to imprinting mutation (also called Prader-Willi syndrome due to imprinting defect or epimutation) is a specific genetic subtype of Prader-Willi syndrome (PWS) caused by abnormal DNA methylation (an epigenetic defect) in the Prader-Willi critical region on chromosome 15q11-q13. In this subtype, both copies of chromosome 15 are present and structurally normal, but the paternal copy carries an abnormal imprinting pattern that silences genes that should normally be active. This imprinting defect accounts for approximately 1–3% of all Prader-Willi syndrome cases. The clinical features are consistent with those seen in other forms of Prader-Willi syndrome. In the neonatal period, affected infants typically present with severe hypotonia (low muscle tone), feeding difficulties, and failure to thrive. During early childhood, the clinical picture shifts dramatically to hyperphagia (an insatiable appetite) and progressive obesity if caloric intake is not strictly controlled. Additional features include short stature, hypogonadism, intellectual disability (usually mild to moderate), behavioral problems (such as temper tantrums, stubbornness, and obsessive-compulsive tendencies), and characteristic facial features including a narrow forehead, almond-shaped eyes, and a thin upper lip. Multiple body systems are affected, including the endocrine, neurological, musculoskeletal, and reproductive systems. There is no cure for Prader-Willi syndrome due to imprinting mutation. Management is multidisciplinary and includes growth hormone therapy to improve height, body composition, and muscle tone; strict dietary supervision to prevent life-threatening obesity; sex hormone replacement for hypogonadism; and behavioral, educational, and psychological support. Early intervention with physical therapy, speech therapy, and occupational therapy can improve developmental outcomes. Notably, some imprinting defect cases occur without a detectable microdeletion in the imprinting center, and these cases may have a lower recurrence risk compared to those with an identifiable imprinting center deletion, which is an important consideration for genetic counseling.
Clinical phenotype terms— hover any for plain English:
Variable
Can be inherited in different ways depending on the underlying gene
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
1 availableVoranigo
indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrog…
indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection
Clinical Trials
View all trials with filters →No actively recruiting trials found for Prader-Willi syndrome due to imprinting mutation at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Prader-Willi syndrome due to imprinting mutation.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Prader-Willi syndrome due to imprinting mutation.
Community
No community posts yet. Be the first to share your experience with Prader-Willi syndrome due to imprinting mutation.
Start the conversation →Latest news about Prader-Willi syndrome due to imprinting mutation
No recent news articles for Prader-Willi syndrome due to imprinting mutation.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Prader-Willi syndrome due to imprinting mutation
What is Prader-Willi syndrome due to imprinting mutation?
Prader-Willi syndrome due to imprinting mutation (also called Prader-Willi syndrome due to imprinting defect or epimutation) is a specific genetic subtype of Prader-Willi syndrome (PWS) caused by abnormal DNA methylation (an epigenetic defect) in the Prader-Willi critical region on chromosome 15q11-q13. In this subtype, both copies of chromosome 15 are present and structurally normal, but the paternal copy carries an abnormal imprinting pattern that silences genes that should normally be active. This imprinting defect accounts for approximately 1–3% of all Prader-Willi syndrome cases. The cli
At what age does Prader-Willi syndrome due to imprinting mutation typically begin?
Typical onset of Prader-Willi syndrome due to imprinting mutation is neonatal. Age of onset can vary across affected individuals.